Search Filters

Search Results

Found 3 results

510(k) Data Aggregation

    K Number
    K243828
    Manufacturer
    Date Cleared
    2025-05-02

    (140 days)

    Product Code
    Regulation Number
    882.5810
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    CIONIC Inc.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Cionic Neural Sleeve NS-200 is intended to provide ankle dorsiflexion and/or plantarflexion and/or eversion in adult individuals with foot drop and/or to assist knee flexion or extension in adult individuals with muscle weakness related to upper motor neuron disease/injury (e.g. stroke, damage to pathways to the spinal cord). The Cionic Neural Sleeve NS-200 electrically stimulates muscles in the affected leg to provide ankle dorsiflexion and/or plantarflexion and/or eversion of the foot and/or knee flexion or extension; thus, it also may improve the individual's gait.

    The Cionic Neural Sleeve NS-200 may also:

    • Facilitate muscle re-education
    • Prevent/retard disuse atrophy
    • Maintain or increase joint range of motion
    • Increase local blood flow

    As a powered muscle stimulator the Cionic Neural Sleeve NS-200 is indicated for the following conditions:

    • Relaxation of muscle spasm

    As a biofeedback device the Cionic Neural Sleeve NS-200 is indicated for the following conditions:

    • Biofeedback, relaxation and muscle re-education purposes
    Device Description

    Same as the primary predicate device, the Cionic Neural Sleeve NS-100 (K221823), the Cionic Neural Sleeve NS-200 is a platform for the measurement and augmentation of lower limb mobility composed of a body-worn legging, a battery-powered electronic controller and a mobile application. The Cionic Neural Sleeve NS-200 has embedded sensors to measure limb movement and muscle activity. These data are used by the control unit to generate stimulation intended to activate muscles for exercise or functional assistance.

    The Cionic Neural Sleeve NS-200 system sales carton consists of the following components:

    1. SL-200 a fabric sleeve covering the upper and lower leg containing embedded motion sensors and skin-contacting electrodes. Left and right leg sleeves are available in four sizes: extra-small, small, medium, and large.

    2. DC-200 a portable battery-powered Control and Stimulation Unit that connects to, and is worn within the SL-200. The DC-200 communicates over Bluetooth™Low Energy protocol to the Cionic mobile application ("Cionic app").

    3. Power supply and cable to recharge the DC-200 and connect the DC-200 to a user's computer when required.

    4. Adhesive, electrically conductive and replaceable electrode pads.

    5. Electrode cover sheets.

    6. Instructions for Use documents.

    Components are available as accessories to the Cionic Neural Sleeve NS-200 system:

    • Replacement electrode pads.

    The Cionic Neural Sleeve NS-200 requires a password-protected Cionic mobile application that is exclusively available to Cionic Neural Sleeve NS-200 iOS and Android users.

    The Cionic Neural Sleeve NS-200 system consists of a software and hardware architecture that enables users to access a library exercise and programs. Programs can be added and removed from the user's mobile app by the user. All exercise and assistance programs utilize a standard calibration and stimulation user interface that is extendible to future exercise and augmentation programs.

    The following minor hardware/mechanical changes have been made to the NS-100 (K221823) and incorporate in the NS-200:

    1. Simplified Sleeve Electronics
      By relocating the electromyography (EMG) circuitry to the Control Unit (DC-200), the redesigned Sleeve (SL-200) is now lighter, more streamlined, and requires less power—delivering a more comfortable and efficient experience for users.

    2. Enhanced Control Unit Grip
      The Control Unit (DC-200) now features integrated side grips, making it easier to connect and disconnect from the sleeve cable—while maintaining the same compact form factor users love.

    3. More Secure Fit, All Day Comfort
      Enhanced Velcro sections on the Sleeve (SL-200) offer improved adherence and a more secure fit, supporting confident wear and optimal electrode positioning throughout the day.

    AI/ML Overview

    The provided text is a 510(k) clearance letter and summary for the Cionic Neural Sleeve NS-200. It describes the device's technical characteristics and its substantial equivalence to predicate devices. However, the document does NOT contain information about acceptance criteria or specific study results that prove the device meets performance criteria, especially concerning the new functionality of advanced biofeedback within the NS-200.

    The document states:

    • "The tests listed have been conducted to demonstrate that the Cionic Neural Sleeve NS-200 performs as intended and is substantially equivalent to both predicate devices."
    • "The Cionic Neural Sleeve NS-200 has been verified and validated successfully for its intended use through a combination of original bench testing and verification and validation of all software and firmware."

    This indicates that testing was done, but the details of the acceptance criteria, specific performance metrics, and the results of those tests are not included in this publicly available clearance letter. For example, while it mentions "Stimulation Output Waveforms" and "Stimulation Output Specifications" as tests conducted, it doesn't provide the target waveform characteristics (acceptance criteria) or the measured waveform characteristics (reported performance).

    Similarly, for the "New Functionality in NS-200" related to biofeedback (Visual Biofeedback Mode and Muscle Activated Stimulation Mode), the document describes how it works but doesn't provide any quantitative acceptance criteria for its performance (e.g., accuracy of sEMG detection, latency of stimulation trigger).

    Therefore, based solely on the provided text, I cannot fulfill most of your request for specific acceptance criteria and study results. The information is simply not present in this type of FDA document, which focuses on substantial equivalence for market clearance rather than detailed performance study reporting.

    However, I can extract and infer some high-level information and point out what is missing:


    Inferred/Missing Information based on the Provided Text:

    Based on the nature of a 510(k) clearance and the information provided, the "acceptance criteria" here are implicitly tied to demonstrating substantial equivalence to predicate devices and meeting relevant safety and performance standards. The "study" mentioned is primarily focused on non-clinical bench testing and software validation.

    Table of Acceptance Criteria and Reported Device Performance (Inferred/Missing)

    Feature/Test AreaAcceptance Criteria (Implicit for Substantial Equivalence/Standards)Reported Device Performance (Specifics NOT provided in document)
    Stimulation Output WaveformsShould match specified waveform characteristics (e.g., rectangular, monophasic with hybrid stimulation) and demonstrate stability/consistency."Tests conducted" but specific measurement values (e.g., actual waveform shape, consistency over time) not provided.
    Stimulation Output SpecificationsShould meet specified ranges for Max Output Voltage, Max Output Current, Pulse Width, Frequency, Net Charge, Max Phase Charge.Values provided in comparison tables (e.g., 50V @ 500Ω, 100mA @ 500Ω, 100-400μs, 5-125Hz). Implicitly met, but no specific "performance" results given as "was measured at X."
    Stimulation Virtual Output ChannelsProper functioning and selection of all 24 virtual channels."Tests conducted" but no specific performance data given (e.g., success rate of channel selection).
    Stimulation Output Channel IsolationMeet specified isolation levels (e.g., -33 dB typical, -70 dB crosstalk) and demonstrate no unintended stimulation."Tests conducted" and implied to meet, citing IC manufacturer datasheet and bench test. No specific quantified result.
    Hybrid StimulationOperates as designed, delivering 0 µC net charge using its hybrid method."Tests conducted" and implied to meet. No specific quantified result.
    Stimulation Electrodes Short and/or Open DetectionSystem detects and responds appropriately to short/open circuit conditions."Tests conducted" but no specific performance data given (e.g., detection accuracy, response time).
    Wireless CoexistenceDevice functions without interference from/to other wireless devices."Tests conducted" but no specific performance data given (e.g., interference levels, reliability).
    Electrical Safety (IEC 60601-1, -1-11; -2-10)Compliance with all relevant clauses of these standards (e.g., leakage current limits, patient protection, functional safety for nerve stimulators)."Passed" (stated compliance with standards). No specific measured values.
    Electromagnetic Compatibility (IEC 60601-1-2)Compliance with EMC requirements (e.g., emission limits, immunity to interference)."Passed" (stated compliance with standards). No specific measured values.
    Software Validation (IEC 62304)Software performs as intended, free from critical bugs, meets design specifications (including new biofeedback features)."Verified and validated successfully." No specific test results, bug counts, or performance metrics.
    Usability (IEC 62366, IEC 60601-1-6)Device is safe and effective for use by intended users, minimal use errors."Leveraged from the predicate device submission." No new specific usability study results for NS-200.
    EMG Performance (Sensitivity, Sampling Rate, Range, Bandwidth, Processing)Meet specified values/ranges and accurately detect muscle activity as intended for biofeedback.Values provided (e.g., 0.0298 μV sensitivity, 2kHz sampling rate, +/-2.5*10⁶ μV range, 10-500 Hz bandwidth, RMS processing). Implicitly met, but no specific "performance" results given as "was measured at X."
    Biofeedback Mode FunctionalityVisual biofeedback accurately reflects muscle activation; Muscle Activated Stimulation triggers consistently at 20% max activation.Functionality described, but no quantitative performance data (e.g., accuracy of visual display, trigger latency, false positive/negative rates for stimulation).
    Clinical Performance (Gait Improvement, Muscle Re-education, etc.)Device provides intended therapeutic effects as described in Indications for Use.Supported by "Summary of Literature Clinical Data" referencing an article on "Adaptive Functional Electrical Stimulation." No direct clinical trial results for NS-200 itself are presented here.

    Specific Information Requested and What is Available/Missing:

    1. A table of acceptance criteria and the reported device performance:

      • Acceptance Criteria: Mostly implicit compliance with safety standards (IEC 60601 series, 21 CFR 898) and technical specifications (e.g., voltage/current ranges, EMG parameters) for substantial equivalence to predicates. Explicit, quantitative acceptance thresholds for performance tests are not provided.
      • Reported Device Performance: Specific quantitative results from testing (e.g., "The measured output voltage was XV, meeting the Y-V criterion") are not provided. The document states that tests "have been conducted" and the device "has been verified and validated successfully," implying compliance, but no actual performance data is listed. The tables compare specifications between devices, not measured performance results.
    2. Sample sizes used for the test set and the data provenance:

      • Test Set Sample Size: Not provided. The testing described is primarily non-clinical bench testing and software validation, not typically expressed in terms of "sample size" of subjects/patients.
      • Data Provenance: The "Summary of Literature Clinical Data" references an article (https://www.medrxiv.org/content/10.1101/2022.04.27.22273623v2.full), which would be the source of any clinical data used to support the new indication for foot eversion. The document itself does not provide details on the study design or provenance of the data within that article.
      • Retrospective/Prospective: Not specified for the non-clinical tests. For the referenced clinical article, it would depend on the study design of that external publication.
    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • Not applicable / Not provided. The document describes non-clinical and software validation tests. There is no mention of "ground truth" adjudicated by experts for a test set in the context of AI/ML performance evaluation, as this is a medical device (neuromuscular stimulator) rather than an AI diagnostic algorithm.
    4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

      • Not applicable / Not provided. As above, this type of adjudication is typically for establishing ground truth in image interpretation or similar expert-driven data labeling, which is not described for this device's clearances.
    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • Not applicable / Not done (as described). An MRMC study is relevant for AI-assisted diagnostic tools. The Cionic Neural Sleeve is a functional neuromuscular stimulator; its clearance focuses on its mechanism of action, safety, and functionality, not its ability to assist human "readers" in interpreting data.
    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

      • Not explicitly stated as such. The device does have a software component with "advanced biofeedback capabilities." The software validation (IEC 62304) would assess the standalone performance of the algorithms. However, "standalone performance" in the context of AI often refers to metrics like AUC, sensitivity, specificity, etc., which are not provided here for any specific task. The document only confirms that the software was "verified and validated successfully."
    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

      • For the non-clinical bench testing: The "ground truth" would be established by reference standards, calibrated equipment, and engineering specifications. For instance, a voltage meter would provide "ground truth" for output voltage.
      • For the software validation: "Ground truth" would be defined by the software's design specifications and expected behavior.
      • For the clinical support: The document references a published article ("Augmenting Gait in a Population Exhibiting Foot Drop with Adaptive Functional Electrical Stimulation"). The ground truth within that study would depend on its specific methodology (e.g., kinematic analysis, clinical outcome measures). The 510(k) does not perform primary ground truth establishment for clinical outcomes itself but rather leverages existing literature.
    8. The sample size for the training set:

      • Not provided (and likely not applicable in the traditional AI/ML sense). The software features described (Visual Biofeedback Mode, Muscle Activated Stimulation Mode) are based on sEMG functionality. While such systems might involve some level of calibration or adaptive algorithms, the document doesn't mention a "training set" in the context of a machine learning model that learns from large datasets. Any internal calibration routines would be part of the software's inherent design, not a separate "training set" for a generalizable AI model.
    9. How the ground truth for the training set was established:

      • Not applicable / Not provided for the reasons stated above.

    In summary, this FDA 510(k) clearance document primarily serves to demonstrate substantial equivalence to existing devices based on technical specifications and compliance with recognized safety and performance standards via non-clinical bench testing and software validation. It is not a detailed clinical study report or an AI/ML algorithm validation report that would contain the specific performance metrics and ground truth establishment details you requested.

    Ask a Question

    Ask a specific question about this device

    K Number
    K221823
    Manufacturer
    Date Cleared
    2022-07-21

    (28 days)

    Product Code
    Regulation Number
    882.5810
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    CIONIC

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Cionic Neural Sleeve NS-100 is intended to provide ankle dorsiflexion in adult individuals with foot drop and/or to assist knee flexion or extension in adult individuals with muscle weakness related to upper motor neuron disease /injury (e.g. stroke, damage to pathways to the spinal cord). The Cionic Neural Sleeve NS-100 electrically stimulates muscles in the affected leg to provide ankle dorsiflexion of the foot and/or knee flexion or extension; thus, it also may improve the individual's gait.

    The Cionic Neural Sleeve NS-100 may also:

    • Facilitate muscle re-education
    • Prevent/retard disuse atrophy
    • Maintain or increase joint range of motion
    • Increase local blood flow
    Device Description

    The Cionic Neural Sleeve NS-100 is a platform for the measurement and augmentation of lower limb mobility composed of a body-worn legging, a battery-powered electronic controller and a mobile application. The Cionic Neural Sleeve NS-100 has embedded sensors to measure limb movement and muscle activity. These data are used by the control unit to generate stimulation intended to activate muscles for exercise or functional assistance.

    The Cionic Neural Sleeve NS-100 system sales carton consists of the following components:

      1. SL-100 a fabric sleeve covering the upper and lower leg containing embedded motion sensors and skin-contacting electrodes. Left and right leg sleeves are available in two sizes: small, and medium.
      1. DC-100 a portable battery-powered Control and Stimulation Unit that connects to, and is worn within the SL-100. The DC-100 communicates over Bluetooth™Low Energy protocol to the Cionic mobile application ("Cionic app").
      1. Power supply and cable to recharge the DC-100 and connect the DC-100 to a user's computer when required.
      1. Adhesive, electrically conductive and replaceable electrode pads.
      1. Electrode cover sheets.
      1. Instructions for Use documents.

    Components are available as accessories to the Cionic Neural Sleeve NS-100 system:

    • o Replacement electrode pads.
      The Cionic Neural Sleeve NS-100 requires a password-protected Cionic mobile application that is exclusively available to Cionic Neural Sleeve NS-100 iOS and Android users.

    The Cionic Neural Sleeve NS-100 system consists of a software and hardware architecture that enables users to access a library exercise and augmentation programs. Programs can be added and removed from the user's mobile app. All exercise and assistance programs utilize a standard calibration and stimulation user interface that is extendible to future exercise and augmentation programs.

    AI/ML Overview

    This 510(k) submission (K221823) from Cionic, Inc. is a Special 510(k) submission to add compatibility of the Cionic Neural Sleeve to support the Android operating system and minor software updates to improve overall stability and performance. As such, the submission primarily focuses on software verification and validation, along with wireless coexistence testing. The claim of substantial equivalence is made with respect to the predicate device, also the Cionic Neural Sleeve NS-100 (K213622).

    Here's an analysis of the acceptance criteria and study information provided:

    1. Table of Acceptance Criteria and Reported Device Performance:

    Acceptance Criteria / TestReported Device Performance
    New tests performed for this submission:
    Wireless Coexistence (according to FDA Guidance Radio Frequency Wireless Technology in Medical Devices Guidance for Industry and Food and Drug Administration Staff Document Issued on: August 14, 2013)Performed to ensure no loss of original functionality. (Specific results not detailed in this summary, but implies successful completion)
    Software Validation (according to IEC 62304)Performed to ensure no loss of original functionality. (Specific results not detailed in this summary, but implies successful completion)
    Leveraged from predicate device (K213622) as modifications did not affect these areas:
    Stimulation Output Waveforms(Assumed to meet criteria from predicate)
    Biological evaluation of medical devices (according to ISO 10993-1)(Assumed to meet criteria from predicate)
    Stimulation Output Specifications(Assumed to meet criteria from predicate)
    Stimulation Virtual Output Channels(Assumed to meet criteria from predicate)
    Stimulation Output Channel Isolation(Assumed to meet criteria from predicate)
    Hybrid Stimulation(Assumed to meet criteria from predicate)
    Stimulation Electrodes Short and/or Open detection(Assumed to meet criteria from predicate)
    Electrical Safety (according to IEC 60601-1; IEC 60601-1-11)(Assumed to meet criteria from predicate)
    Muscle and Nerve Stimulators (according to IEC 60601-2-10)(Assumed to meet criteria from predicate)
    Electromagnetic compatibility (according to IEC 60601-1-2)(Assumed to meet criteria from predicate)
    Usability (according to IEC 62366; IEC 60601-1-6)(Assumed to meet criteria from predicate)
    Mobile Application OS Compatibility (specifically, addition of Android compatibility, risk analysis and testing)Risk analysis and testing demonstrate substantial equivalence. (Implies successful testing for Android OS)

    2. Sample Size Used for the Test Set and Data Provenance:

    The provided 510(k) summary does not detail specific sample sizes for the test sets. For software validation and wireless coexistence, these typically involve testing on the device itself and against relevant communication standards. No patient data or clinical study details are provided in this summary. Therefore, there's no information on the country of origin of data or whether it was retrospective or prospective.

    3. Number of Experts Used to Establish Ground Truth and Qualifications:

    Not applicable. This submission is for a software/OS compatibility update and does not involve clinical performance assessment requiring expert opinion for ground truth establishment.

    4. Adjudication Method for the Test Set:

    Not applicable. The tests performed are primarily engineering and software validation tests (wireless coexistence, software validation) and do not involve subjective interpretation requiring adjudication.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:

    No, an MRMC comparative effectiveness study was not done. This submission is for a software and OS compatibility update, not for establishing clinical effectiveness or comparing human reader performance with and without AI assistance.

    6. If a Standalone (i.e., algorithm-only without human-in-the-loop performance) was done:

    Not explicitly stated in terms of "standalone performance" in the context of an algorithm assessing medical images or data without human input. However, the software validation and wireless coexistence tests verify the system's technical functionality, which is an evaluation of the system's independent operation (without direct human user intervention during the specific test runs, although the device is designed for human interaction). There's no separate mention of an algorithm's standalone performance in a diagnostic or clinical decision-making capacity.

    7. The Type of Ground Truth Used:

    For the software and wireless coexistence tests, the ground truth would be defined by the technical specifications and standards (e.g., IEC 62304 for software, FDA guidance for wireless coexistence, Bluetooth Low Energy specifications for communication). The purpose of the tests is to verify that the device's software and communication capabilities adhere to these established technical requirements.

    8. The Sample Size for the Training Set:

    Not applicable. This is not an AI/ML device submission in the sense of a new algorithm being trained. The submission refers to "minor software updates" and "stability and performance" improvements. Therefore, there's no mention of a training set or machine learning model training in this context.

    9. How the Ground Truth for the Training Set Was Established:

    Not applicable, as there is no training set for an AI/ML algorithm mentioned in this submission.

    Ask a Question

    Ask a specific question about this device

    K Number
    K213622
    Manufacturer
    Date Cleared
    2022-02-14

    (90 days)

    Product Code
    Regulation Number
    882.5810
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    CIONIC

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Cionic Neural Sleeve NS-100 is intended to provide ankle dorsiflexion in adult individuals with foot drop and/or to assist knee flexion or extension in adult individuals with muscle weakness related to upper motor neuron disease /injury (e.g. stroke, damage to the spinal cord). The Cionic Neural Sleeve NS-100 electrically stimulates muscles in the affected leg to provide ankle dorsiflexion of the foot and/or knee flexion or extension; thus, it also may improve the individual's gait.

    The Cionic Neural Sleeve NS-100 may also:

    • Facilitate muscle re-education
    • Prevent/retard disuse atrophy
    • Maintain or increase joint range of motion
    • Increase local blood flow
    Device Description

    The Cionic Neural Sleeve NS-100 is a platform for the measurement and augmentation of lower limb mobility composed of a body-worn legging, a battery-powered electronic controller and a mobile application. The Cionic Neural Sleeve NS-100 has embedded sensors to measure limb movement and muscle activity. These data are used by the control unit to generate stimulation intended to activate muscles for exercise or functional assistance.

    The Cionic Neural Sleeve NS-100 is intended to provide ankle dorsiflexion and/or plantarflexion in adult individuals with foot drop and/or to assist knee flexion or extension in adult individuals with muscle weakness related to upper motor neuron disease/injury (e.g. stroke, damage to pathways to the spinal cord). The Cionic Neural Sleeve NS-100 electrically stimulates muscles in the affected leg to provide ankle dorsiflexion and/or plantarflexion of the foot and/or knee flexion or extension; thus, it also may improve the individual's gait.

    The Cionic Neural Sleeve NS-100 system sales carton consists of the following components:

      1. SL-100 a fabric sleeve covering the upper and lower leg containing embedded motion sensors and skin-contacting electrodes. Left and right leg sleeves are available in two sizes: small, and medium.
      1. DC-100 a portable battery-powered Control and Stimulation Unit that connects to, and is worn within the SL-100. The DC-100 communicates over Bluetooth™Low Energy protocol to the Cionic mobile application ("Cionic app").
      1. Power supply and cable to recharge the DC-100 and connect the DC-100 to a user's computer when required.
      1. Adhesive, electrically conductive and replaceable electrode pads.
      1. Electrode cover sheets.
      1. Instructions for Use documents.

    Components are available as accessories to the Cionic Neural Sleeve NS-100 system:

    • Replacement electrode pads.
      The Cionic Neural Sleeve NS-100 requires a password-protected Cionic mobile application that is exclusively available to Cionic Neural Sleeve NS-100 users.

    The Cionic Neural Sleeve NS-100 system consists of a software and hardware architecture that enables users to access a library exercise and augmentation programs. Programs can be added and removed from the user's mobile app. All exercise and assistance programs utilize a standard calibration and stimulation user interface that is extendible to future exercise and augmentation programs.

    AI/ML Overview

    The provided FDA 510(k) summary for the Cionic Neural Sleeve NS-100 (K213622) does not include a detailed study proving the device meets specific acceptance criteria based on performance metrics such as sensitivity, specificity, accuracy, or effect size for human readers with AI assistance.

    The document focuses on demonstrating substantial equivalence to a predicate device (Bioness L300 Go System, K190285) rather than providing a standalone performance study with quantified acceptance criteria for diagnostic or assistive accuracy. The performance data presented is limited to non-clinical testing for safety and technical specifications, not clinical effectiveness in terms of how well it improves patient outcomes or how it performs against a measurable clinical metric.

    Therefore, many of the requested items cannot be extracted directly from this document. However, I can provide what is available and clarify what is missing.


    Acceptance Criteria and Device Performance (Based on Technical and Safety Testing)

    While the document doesn't list quantitative clinical performance criteria, it outlines the non-clinical tests conducted to demonstrate the device performs as "intended" and is "substantially equivalent." The "reported device performance" in this context refers to its adherence to these technical and safety standards.

    Acceptance Criteria (Implied by non-clinical tests)Reported Device Performance
    Safety and Electrical Performance:Demonstrated Compliance:
    Compliance with IEC 60601-1 (Electrical Safety)Compliant (Implied by "successfully verified/validated," "adhere to recognized/consensus electrical safety standards")
    Compliance with IEC 60601-1-11 (Electrical Safety in Home Healthcare)Compliant (Implied by "successfully verified/validated," "adhere to recognized/consensus electrical safety standards")
    Compliance with IEC 60601-2-10 (Muscle and Nerve Stimulators)Compliant (Implied by "successfully verified/validated," "adhere to recognized/consensus electrical safety standards")
    Compliance with IEC 60601-1-2 (Electromagnetic Compatibility)Compliant
    Battery Safety (IEC 62133-2)Compliant
    Stimulation Output Waveforms meet specificationsPerformed as intended
    Stimulation Output Channels and Isolation meet specificationsPerformed as intended
    Hybrid Stimulation functions as intendedPerformed as intended
    Stimulation Electrodes Short and/or Open detection functions as intendedPerformed as intended
    Biocompatibility:
    Biological evaluation of medical devices according to ISO 10993-1Compliant
    Usability and Software:
    Usability according to IEC 62366; IEC 60601-1-6Compliant ("successfully verified/validated")
    Software validation according to IEC 62304Compliant ("successfully verified/validated")
    Functional/Technological Equivalence (to Predicate):
    Provide ankle dorsiflexion and/or plantarflexion, assist knee flexion or extensionYes, similar indications, with additional plantarflexion capability compared to predicate.
    Facilitate muscle re-education, prevent/retard disuse atrophy, maintain/increase ROM, increase local blood flowYes, similar to predicate.
    Other technological characteristics (e.g., output current, power density, control methods)Found "Substantially equivalent," with differences considered minor and having no impact on safety and effectiveness.

    Detailed Information Regarding Study (Based on Document Analysis):

    1. Sample size used for the test set and the data provenance:

      • Sample Size: Not applicable/not provided in this summary. The document describes non-clinical bench testing and verification/validation processes, not a clinical study on a patient test set with performance metrics.
      • Data Provenance: Not applicable, as it's not a clinical data set. It refers to non-clinical testing performed by the manufacturer, Cionic, Inc.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • Not applicable. Ground truth as typically defined for clinical or diagnostic performance studies is not established in this document, as it outlines technical and safety testing.
    3. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

      • Not applicable. There is no mention of a human-reviewed test set or adjudication process for clinical performance.
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No. This is not an MRMC comparative effectiveness study involving human readers or AI assistance in a diagnostic context. The device is a functional neuromuscular stimulator, not an AI-assisted diagnostic tool.
    5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

      • The document implies extensive standalone engineering verification and validation of the device's electrical, mechanical, software, and biocompatibility aspects. However, this is not a clinical "standalone performance" in the sense of an algorithm making a clinical decision without human intervention. The device's function is to directly stimulate muscles based on detected limb movement.
      • The software was validated according to IEC 62304, and the overall system was "verified and validated successfully for its intended use through a combination of original bench testing and verification and validation of all software and firmware."
    6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

      • For the non-clinical testing, the "ground truth" was compliance with established engineering standards (e.g., IEC standards for electrical safety, biocompatibility, usability, software validation) and the device's design specifications. There is no clinical outcomes data or pathology-based ground truth presented in this summary for the purpose of demonstrating substantial equivalence.
    7. The sample size for the training set:

      • Not applicable. This document does not describe an AI/machine learning model that would require a "training set" in the traditional sense for diagnostic or predictive performance. The device uses embedded sensors and a control unit to generate stimulation for functional assistance, implying a rule-based or control-loop system rather than a trained AI classification model.
    8. How the ground truth for the training set was established:

      • Not applicable, as there is no mention of a training set for an AI/machine learning model.

    Summary of Conclusions from the Document:

    The Cionic Neural Sleeve NS-100 underwent comprehensive non-clinical testing, including electrical safety, biocompatibility, usability, and software validation. Based on the results, Cionic Inc. concluded that the device is substantially equivalent to the predicate Bioness L300 Go System. The differences noted, such as the ability to provide plantarflexion and variations in technological characteristics (e.g., number of output modes, power sources, stimulation channels, clinician/user control interfaces, and trigger sources), were deemed "minor with no impact to safety and effectiveness" because they either represented a subset of the predicate's capabilities, adhered to recognized safety standards, or achieved similar functional outcomes through different but validated technological means.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1